http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Savara Announces New Employment Inducement Grant
-
Savara (SVRA) Announces Expanded Access Program for Molgramostim Inhalation Solution for Patients with Autoimmune Pulmonary Alveolar Proteinosis
-
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
-
Savara (SVRA) Appoints Braden Parker as Chief Commercial Officer
-
Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately
-
Savara to Host Analyst and Investor Webinar on September 30, 2024
-
Savara (SVRA) Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution
-
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the
-
Savara Announces New Employment Inducement Grant
-
Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
-
Savara Announces New Employment Inducement Grant
-
Savara (SVRA) to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis
-
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respi
-
Savara Reports Second Quarter 2024 Financial Results and Provides Business Update
-
Savara (SVRA) Reports Molgramostim Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2
-
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in
-
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosi
-
Savara to Present at the Jefferies Global Healthcare Conference
-
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
-
Savara Announces New Employment Inducement Grant
-
Savara Reports First Quarter 2024 Financial Results and Provides Business Update
-
Savara to Present at the Citizens JMP Life Sciences Conference
-
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
-
Savara Announces New Employment Inducement Grant
-
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
-
Savara to Present at the Barclays 26th Annual Global Healthcare Conference
-
Savara Announces New Employment Inducement Grant
-
Savara to Present at Two Upcoming Healthcare Conferences
-
Savara (SVRA) Introduces aPAP ClearPath
-
Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
-
Savara Added to the NASDAQ Biotechnology Index
-
Savara Announces New Employment Inducement Grant
-
Savara to Present at the Piper Sandler 35th Annual Healthcare Conference
-
Savara Reports Third Quarter Financial Results and Provides Business Update
-
Savara to Present at the Jefferies London Healthcare Conference
-
Savara Announces New Employment Inducement Grant
-
Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference
-
Savara Reports Second Quarter Financial Results and Provides Business Update
-
Savara Announces New Employment Inducement Grant
-
Savara (SVRA) added to Russell 3000
-
Savara Added to Russell 3000® Index
-
Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
-
Savara to Present at the Jefferies Healthcare Conference
-
Savara Reports First Quarter Financial Results and Provides Business Update
-
Savara Announces New Employment Inducement Grant
-
Savara Announces New Employment Inducement Grant
-
Savara Reports Fourth Quarter / Year-End 2022 Financial Results and Provides Business Update
-
Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference
-
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Savara (SVRA) Announces Leadership Appointments

